Neurology remains key therapeutic area for Japan pharma majors: GlobalData
Express Pharma
MAY 30, 2024
According to GlobalData’s Pharmaceutical Intelligence Center, for instance, the number of diagnosed prevalent cases of Alzheimer’s disease (excluding mild cognitive impairment) across major markets in APAC (Australia, China, India, Japan, South Korea) is expected to increase at an average annual growth rate (AGR) of 4.54 per cent from 7.45
114 
Let's personalize your content